162 related articles for article (PubMed ID: 22680772)
1. Interim response assessment for Hodgkin lymphoma: size matters.
Elstrom RL
Leuk Lymphoma; 2012 Nov; 53(11):2095-6. PubMed ID: 22680772
[No Abstract] [Full Text] [Related]
2. Hodgkin lymphoma-associated paraneoplastic cerebellar degeneration on FDG-PET/CT.
Gheysens O; Deroose CM; Tousseyn T; Goffin K; Verhoef G; Dierickx D
Br J Haematol; 2014 Feb; 164(4):468. PubMed ID: 24460525
[No Abstract] [Full Text] [Related]
3. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
Kostakoglu L; Schöder H; Johnson JL; Hall NC; Schwartz LH; Straus DJ; LaCasce AS; Jung SH; Bartlett NL; Canellos GP; Cheson BD;
Leuk Lymphoma; 2012 Nov; 53(11):2143-50. PubMed ID: 22421007
[TBL] [Abstract][Full Text] [Related]
4. Flip-flop pattern of skeleton after treatment in a patient with Hodgkin's lymphoma.
Sahiner I; Akkas BE; Demirel BB; Vural GU
Rev Esp Med Nucl Imagen Mol; 2013; 32(4):277-8. PubMed ID: 23578983
[No Abstract] [Full Text] [Related]
5. Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin lymphoma.
Marzolini M; Wong WL; Ardeshna K; Padhani A; D'Sa S
Br J Haematol; 2012 Mar; 156(5):557. PubMed ID: 22150023
[No Abstract] [Full Text] [Related]
6. Intravenacaval invasion of classical Hodgkin lymphoma detected with
Makita S; Kurihara H; Tobinai K
Lancet Oncol; 2017 Apr; 18(4):e233. PubMed ID: 28368262
[No Abstract] [Full Text] [Related]
7. Update on Hodgkin lymphoma from a radiologist's perspective.
Levine I; Kalisz K; Smith DA; Tirumani SH; Ramaiya NH; Alessandrino F
Clin Imaging; 2020 Sep; 65():65-77. PubMed ID: 32361412
[TBL] [Abstract][Full Text] [Related]
8. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Cheson BD
Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
[TBL] [Abstract][Full Text] [Related]
9. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
10. Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy?
Yeoh KW; Mikhaeel NG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):14-20. PubMed ID: 22578540
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
12. Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
Adams HJ; Kwee TC
Nucl Med Commun; 2016 Dec; 37(12):1333-1334. PubMed ID: 27501435
[No Abstract] [Full Text] [Related]
13. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
14. Value of positron emission tomography in diagnosing subcutaneous panniculitis-like T-cell lymphoma.
Bennani-Baiti B; Yadav S; Flynt L; Bennani-Baiti N
J Clin Oncol; 2015 Apr; 33(10):1216-7. PubMed ID: 25691676
[No Abstract] [Full Text] [Related]
15. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
16. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma.
Kobe C; Dietlein M; Fuchs M
Leuk Lymphoma; 2010 Mar; 51(3):552-3. PubMed ID: 20141443
[No Abstract] [Full Text] [Related]
17. Lymphoma and tuberculosis: temporal evolution of dual pathology on sequential 18F-FDG PET/CT.
Mukherjee A; Sharma P; Karunanithi S; Dhull VS; Kumar R
Clin Nucl Med; 2014 Aug; 39(8):736-7. PubMed ID: 24566399
[TBL] [Abstract][Full Text] [Related]
18. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
19. FDG uptake in liposclerosing myxofibrous tumor causes upstaging of Hodgkin lymphoma.
Kim J; Chen W; Resnik C; Dilsizian V; Chen Q; Kimball AS
Clin Nucl Med; 2015 Apr; 40(4):325-7. PubMed ID: 25290293
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of FDG-PET cannot be judged by iliac bone marrow biopsy.
Cheng G
Br J Radiol; 2012 Aug; 85(1016):1204-5; author reply 1206-7. PubMed ID: 22815418
[No Abstract] [Full Text] [Related]
[Next] [New Search]
